Table 1.
Baseline Characteristics Classified by Treatment Group
|
All patients
(N = 33) |
Post-PCI
Group (n = 11) |
Post-WBRT
Group (n = 12) |
Upfront SRS
Group (n = 10) |
P value | |
|---|---|---|---|---|---|
| Age, median (range) | 61 (30–76) y | 65 (53–76) y | 62 (45–75) y | 48 (30–62) y | <.001 |
| KPS, median | 80 (60–90) | 80 (70–90) | 80 (60–90) | 90 (80–90) | .081 |
| Sex | .281 | ||||
| Male | 18 (54.5%) | 4 (36.4%) | 7 (58.3%) | 7 (70%) | |
| Female | 15 (45.5%) | 7 (63.6%) | 5 (41.7%) | 3 (30%) | |
| Race | .051 | ||||
| Caucasian | 25 (75.7%) | 10 (90.9%) | 7 (58.3%) | 8 (80%) | |
| Black | 3 (9.1%) | 0 | 3 (25%) | 0 | |
| Hispanic | 3 (9.1%) | 1 (9.1%) | 0 | 2 (20%) | |
| Asian | 2 (6.1%) | 0 | 2 (16.7%) | 0 | |
| Primary site | .047 | ||||
| Lung | 29 (87.9%) | 11 (100%) | 11 (91.7%) | 7 (70%) | |
| Cervix | 2 (6.1%) | 0 | 0 | 2 (20%) | |
| Esophagus | 1 (3.0%) | 0 | 0 | 1 (10%) | |
| Prostate | 1 (3.0%) | 0 | 1 (8.3%) | 0 | |
| Primary histology | .006 | ||||
| Small cell | 23 (69.7%) | 10 (90.9%) | 10 (83.3%) | 3 (30%) | |
| Other NETs | 10 (30.3%) | 1 (9.1%) | 2 (16.7%) | 7 (70%) | |
| Baseline RPA41 | .164 | ||||
| RPA class I | 13 (39.4%) | 2 (18.2%) | 5 (41.7%) | 6 (60%) | |
| RPA class II | 19 (57.6%) | 9 (81.8%) | 6 (50%) | 4 (40%) | |
| RPA class III | 1 (3.0%) | 0 | 1 (8.3%) | 0 | |
| Baseline DS-GPA42 | .032 | ||||
| 0–1.0 | 4 (12.1%) | 1 (9.1%) | 2 (16.7%) | 1 (10%) | |
| 1.5–2.5 | 23 (69.7%) | 10 (90.9%) | 9 (75%) | 4 (40%) | |
| 3.0 | 2 (6.1%) | 0 | 1 (8.3%) | 1 (10%) | |
| 3.5–4.0 | 4 (12.1%) | 0 | 0 | 4 (40%) | |
| Baseline SIR43 | .312 | ||||
| 4–7 | 25 (75.8%) | 10 (90.9%) | 9 (75%) | 6 (60%) | |
| 8–10 | 8 (24.2%) | 1 (9.1%) | 3 (25%) | 4 (40%) | |
| Active extracranial metastasis at diagnosis of brain metastasis | 11 (33.3%) | 3 (27.3%) | 4 (33.3%) | 4 (40%) | .899 |
| Median number of brain metastatic lesions (range) | 3 (1–24) | 3 (1–8) | 3 (1–24) | 3 (1–10) | .603 |
| Median interval between NET diagnosis and brain metastasis diagnosis, months (range) | 8.2 (0–33.3) | 14.2 (8.2–33.3) | 5.5 (0–17.8) | 6.4 (0–31) | .017 |
Abbreviation: DS-GPA, disease-specific grade prognostic assessment; KPS, Karnofsky performance status; PCI, prophylactic cranial irradiation; NETs, neuroendocrine tumors; RPA, recursive partitioning analysis; SIR, score index for radiosurgery; SRS, stereotactic radiosurgery; WBRT, whole brain radiation therapy; y, years.